Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer

Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT07281157 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 30 participants, started 2025-11-01 and due to reach its primary completion in 2027-04-30. Interventions recorded: Irinotecan Liposome, Capecitabine, and Enlansubemab Plus Short-Course Radiotherapy. Conditions listed: Advanced Rectal Cancer. Primary outcome: Complete response plus pathological complete response. Colorectal eligibility wording from the registry: "rectal adenocarcinoma confirmed by histology and/or cytology;". Sites: China. No results are recorded here; the registry entry is the source.